Novartis shares slide after-hours after heart-trial fails to cut events
Novartis shares sank after-hours after a heart-disease trial failed to show that lowering an inherited risk factor prevented heart attacks and strokes. NVS closed at $159.99, then slipped as much as about 7% after hours.